Compare American Financial Group Inc (AFG) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs Amgen, Inc. — how do they compare? American Financial Group Inc trades at $145.17 (market cap $11.97B), while Amgen, Inc. trades at $417.74 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 18.7× American Financial Group Inc's market cap, and American Financial Group Inc pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| AFG | AMGN | |
|---|---|---|
Market Cap | $11.97B | $224.14B |
Sector | Financials | Health |
52-Week High | $148.71 | $417.20 |
52-Week Low | $124.18 | $271.18 |
Enterprise Value | $12.35B | $267.45B |
Dividend Yield | 2.44% | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFG trades at $142.77, down 0.76% on the day, with a bullish technical signal supported by moving averages and a neutral RSI near 59. The stock shows consistent profitability with a net income margin of 11.66% and ROE of 20.41%, though revenue dipped slightly in 2025. Recent Q2 2026 earnings beat estimates, driven by strong P&C underwriting and investment income, as reported by Business Wire on August 4, 2026.
The outlook remains positive with a consensus price target of $160.67, implying 12.5% upside. Risks include potential earnings volatility and competitive pressures in the insurance sector. Analyst sentiment is mixed with 41% buy ratings, but no sell recommendations, supporting a cautiously optimistic view for long-term investors.
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
